Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-04-22FDA Approved: PIOGLITAZONE HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for Pioglitazone hydrochloride, a generic thiazolidinedione used to treat type 2 diabetes mellit…
-
FDA approval · 2015-04-20FDA Approved: AFREZZA — Supplemental Application (Mannkind Corporation)
The FDA approved a supplemental application for AFREZZA (insulin human) submitted by MannKind Corporation.
-
FDA approval · 2015-04-17FDA Approved: NOVOLOG — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for NovoLog (insulin aspart) submitted by Novo Nordisk.
-
FDA approval · 2015-04-17FDA Approved: AFREZZA — Supplemental Application (Mannkind Corporation)
FDA approved a supplemental application for AFREZZA (insulin human) submitted by MannKind Corporation.
-
FDA approval · 2015-04-15FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for bromocriptine mesylate (Padagis US LLC).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-04-13FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Metformin Hydrochloride from Zydus Lifesciences Limited, finalizing a change to this generic pro…
-
FDA approval · 2015-03-20FDA Approved: SYMLINPEN — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for SYMLINPEN (pramlintide acetate) from AstraZeneca Pharmaceuticals LP.
-
FDA approval · 2015-03-16FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for a pioglitazone and glimepiride combination product developed by Prasco Laboratories.
-
FDA approval · 2015-03-12FDA Approved: AFREZZA — Supplemental Application (Mannkind Corporation)
FDA approves a supplemental application for AFREZZA (insulin human) from MannKind Corporation. The approval relates to labeling/indication e…
-
FDA approval · 2015-03-10FDA Approved: JANUVIA — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approves a supplemental application for JANUVIA (sitagliptin) submitted by Merck Sharp & Dohme LLC.
-
FDA approval · 2015-03-09FDA Approved: TRULICITY — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for TRULICITY (dulaglutide) from Eli Lilly and Company.
-
FDA approval · 2015-03-09FDA Approved: LIRAGLUTIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for liraglutide from Teva Pharmaceuticals USA, Inc. The action indicates regulatory approval for pot…
-
FDA approval · 2015-03-03FDA Approved: HUMULIN N — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Humulin N (insulin human) submitted by Eli Lilly and Company.
-
FDA approval · 2015-03-03FDA Approved: INVOKANA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKANA (canagliflozin) submitted by Janssen Pharmaceuticals, Inc., resulting in changes to…
-
FDA approval · 2015-03-03FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKAMET (canagliflozin/metformin HCl) from Janssen Pharmaceuticals.
-
FDA approval · 2015-02-25FDA Approved: TOUJEO — Original Application (Sanofi-Aventis U.S. LLC)
FDA approved Toujeo (insulin glargine) through its original application, establishing a concentrated long-acting insulin product for glycemi…
-
FDA approval · 2015-02-25FDA Approved: LANTUS SOLOSTAR — Supplemental Application (sanofi-aventis U.S. LLC)
FDA approved a supplemental application for Lantus SoloStar (insulin glargine) from sanofi-aventis U.S. LLC. The insulin product is used to …
-
FDA approval · 2015-02-25FDA Approved: INSULIN LISPRO — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for insulin lispro from Eli Lilly, updating approval details for this product.
-
FDA approval · 2015-02-25FDA Approved: SYMLINPEN — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for SymlinPen (pramlintide acetate) by AstraZeneca Pharmaceuticals LP.
-
FDA approval · 2015-02-25FDA Approved: NOVOLIN N — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for NOVOLIN N (human insulin) from Novo Nordisk.
-
FDA approval · 2015-02-25FDA Approved: LIRAGLUTIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for liraglutide (NDA 022341).
-
FDA approval · 2015-02-25FDA Approved: PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for a generic pioglitazone hydrochloride and metformin hydrochloride combination product intende…
-
FDA approval · 2015-02-25FDA Approved: NOVOLOG — Supplemental Application (Novo Nordisk)
The FDA has approved a supplemental application for NOVOLOG (insulin aspart) from Novo Nordisk. The approval relates to changes to the produ…
-
FDA approval · 2015-02-25FDA Approved: APIDRA — Supplemental Application (sanofi-aventis U.S. LLC)
FDA approved a supplemental application for APIDRA (insulin glulisine) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2015-02-25FDA Approved: HUMALOG MIX75/25 — Supplemental Application (Eli Lilly and Company)
FDA approves a supplemental application for Humalog Mix75/25 (insulin lispro) from Eli Lilly and Company.